Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...
A study has found a previously known cancer-related drug aka nivolumab/relatlimab can be repurposed for Parkinson's disease, ...
The U.S. Food and Drug Administration is reviewing a new Parkinson's disease drug called tavapadon that could give people with the disease more control over their movements.
– After 14 days of treatment in healthy volunteers, ARV-102 decreased lysosomal and neuroinflammatory microglial pathway biomarkers known to be elevated in Parkinson’s disease – NEW HAVEN, Conn., Oct.
In the development of Parkinson's disease, it may not be a good idea to turn the amp to 11. High-volume noise exposure ...
In the development of Parkinson’s disease, it may not be a good idea to turn the amp to 11. High-volume noise exposure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback